首頁 > 市場調查報告書 > 製藥

癌症生物製劑

癌症免疫療法市場規模、佔有率和成長分析（按類型、應用、給藥途徑、最終用戶和地區分類）—產業預測，2026-2033年

市場調查報告書

商品編碼

1898321

癌症免疫療法市場規模、佔有率和成長分析（按類型、應用、給藥途徑、最終用戶和地區分類）—產業預測，2026-2033年

Cancer Immunotherapy Market Size, Share, and Growth Analysis, By Type (Monoclonal Antibodies, Cancer Vaccines), By Application (Lung Cancer, Breast Cancer), By Route of Administration, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 197 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球癌症免疫療法市場規模將達到 1,359.3 億美元，到 2025 年將達到 1,473.5 億美元，到 2033 年將達到 2,809.2 億美元，預測期（2026-2033 年）的複合年成長率為 8.4%。

全球癌症免疫療法市場正經歷顯著擴張，這主要得益於癌症發病率的上升、標靶治療需求的成長以及免疫腫瘤學技術的進步。免疫查核點抑制劑，尤其是PD-1/PD-L1和CTLA-4抑制劑，已展現優於傳統治療方法的療效。個人化醫療和CAR-T療法重新定義了癌症治療策略，並在多種癌症類型中取得了持續的療效。強大的研發投入、有利的監管環境以及不斷加強的公私合營，正在推動快速創新，尤其是在黑色素瘤和肺癌等難治性惡性腫瘤領域。然而，不斷上漲的治療成本、低收入地區治療資源的匱乏以及嚴重的免疫相關不利事件仍然是巨大的挑戰。儘管如此，人工智慧的融入正在革新患者篩選和治療最佳化，旨在實現更有效、更公平的癌症治療方案。

全球癌症免疫療法市場促進因素

全球免疫腫瘤市場的成長主要受全球各類癌症發生率上升的驅動。癌症作為全球健康挑戰的主要因素，其日益成長的盛行率凸顯了對創新有效治療方法的迫切需求。肺癌、乳癌、大腸癌、黑色素瘤和血液相關惡性腫瘤等癌症持續影響著相當大比例的人口，因此，對先進治療方案的需求變得愈發迫切。這種情況凸顯了開拓創新策略以應對日益嚴重的全球癌症負擔並改善患者預後的重要性。

全球癌症免疫療法市場面臨的限制因素

癌症發生率的指數級成長促使人們更加關注癌症治療，尤其是免疫療法的研發。隨著這些治療方法的生產和測試規模的擴大，其相關費用往往令患者難以承受，成為市場成長的一大障礙。此外，免疫療法的一些副作用，例如腫脹、皮疹、心悸和頭痛，也會使患者放棄治療。這種猶豫進一步阻礙了癌症免疫療法市場的潛在擴張，凸顯了解決經濟和安全問題以促進這些治療方法更廣泛接受和應用的必要性。

全球癌症免疫療法市場趨勢

全球免疫腫瘤市場的一大趨勢是整合個人化醫療策略。治療方法根據個體的基因譜和腫瘤特徵量身定做，從而提高療效並最大限度地減少副作用。這推動了對創新生物標記驅動治療方法的需求。此外，將免疫療法與化療和標靶治療等傳統療法結合的聯合治療療法也日益普及。對多種癌症類型的日益關注以及包括CAR-T細胞療法和免疫查核點抑制劑在內的新型藥物製劑的出現，進一步塑造了市場格局，從而改善患者預後並增加研發投入。

Merck & Co., Inc.（USA）
Bristol-Myers Squibb Company（USA）
F. Hoffmann-La Roche AG（Switzerland）
AstraZeneca plc（UK）
Regeneron Pharmaceuticals, Inc.（USA）
Gilead Sciences, Inc.（USA）
Novartis AG（Switzerland）
Pfizer Inc.（USA）
Amgen Inc.（USA）
Johnson & Johnson（USA）
BioNTech SE（Germany）
Moderna, Inc.（USA）
Exelixis, Inc.（USA）
Alnylam Pharmaceuticals, Inc.（USA）
Incyte Corporation（USA）
Sanofi SA（France）
BeiGene, Ltd.（China）
Zai Lab Limited（China）
Fate Therapeutics, Inc.（USA）
Kura Oncology, Inc.（USA）

結論與建議

簡介目錄

Product Code: SQMIG35H2344

Global Cancer Immunotherapy Market size was valued at USD 135.93 Billion in 2024 and is poised to grow from USD 147.35 Billion in 2025 to USD 280.92 Billion by 2033, growing at a CAGR of 8.4% during the forecast period (2026-2033).

The global Cancer Immunotherapy market is witnessing significant expansion driven by increasing cancer prevalence, a growing preference for targeted therapies, and advancements in immuno-oncology technologies. Immune checkpoint inhibitors, notably PD-1/PD-L1 and CTLA-4, are proving more effective than traditional treatments. Personalized medicine and CAR-T therapies are redefining treatment approaches, delivering sustainable results for various cancer types. Strong research and development efforts, coupled with favorable regulatory landscapes and enhanced public-private collaborations, are facilitating rapid innovation, especially for challenging malignancies like melanoma and lung cancer. However, high treatment costs, limited accessibility in low-income regions, and severe immune-related adverse effects pose considerable challenges. Nevertheless, the integration of artificial intelligence is revolutionizing patient selection and treatment optimization, ultimately aiming for more effective and equitable cancer care solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Immunotherapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Immunotherapy Market Segments Analysis

Global Cancer Immunotherapy Market is segmented by Type, Application, Route of Administration, End User and region. Based on Type, the market is segmented into Monoclonal Antibodies, Cancer Vaccines, Checkpoint Inhibitors and Immunomodulators. Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Head and Neck Cancer, Prostate Cancer, Colorectal Cancer, Melanoma and Others. Based on Route of Administration, the market is segmented into Intravenous (IV), Intramuscular and Oral. Based on End User, the market is segmented into Hospitals & Clinics, Cancer Research Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Immunotherapy Market

The growth of the global cancer immunotherapy market is primarily driven by the increasing incidence of various cancer types across the globe. The escalating prevalence of cancer, which stands as a leading contributor to global health challenges, underscores the urgent demand for innovative and effective treatment methods. As cancers such as lung, breast, colorectal, melanoma, and blood-related malignancies continue to impact a significant portion of the population, the necessity for advanced therapeutic solutions becomes increasingly critical. This context emphasizes the importance of pioneering new strategies to tackle the rising global cancer burden and improve patient outcomes.

Restraints in the Global Cancer Immunotherapy Market

The rapid rise in cancer prevalence has intensified the focus on research and development in cancer treatments, particularly immunotherapy. As the production and testing of these therapies expand, the associated costs often become prohibitively high for patients, posing a significant barrier to market growth. Additionally, the various side effects linked with immunotherapy, including swelling, skin rashes, heart palpitations, and headaches, can deter patients from pursuing these treatments. This reluctance further undermines the potential expansion of the cancer immunotherapy market, highlighting the need to address both financial and safety concerns to foster wider acceptance and utilization of these therapies.

Market Trends of the Global Cancer Immunotherapy Market

A key market trend in the global cancer immunotherapy landscape is the increasing integration of personalized medicine strategies, as therapies are tailored to individual genetic profiles and tumor characteristics. This approach enhances treatment efficacy and minimizes adverse effects, driving demand for innovative biomarker-driven therapies. Additionally, the expansion of combination therapies, utilizing immunotherapies alongside traditional treatments like chemotherapy and targeted therapies, is gaining traction. The growing focus on addressing various cancer types and the rise of novel drug formulations, including CAR-T cell therapies and immune checkpoint inhibitors, are further shaping the market, leading to improved patient outcomes and heightened investment in research and development.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Cancer Immunotherapy Market Size by Type & CAGR (2026-2033)

Market Overview
Monoclonal Antibodies
Cancer Vaccines
Checkpoint Inhibitors
Immunomodulators

Global Cancer Immunotherapy Market Size by Application & CAGR (2026-2033)

Market Overview
Lung Cancer
Breast Cancer
Head and Neck Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Others

Global Cancer Immunotherapy Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Intravenous (IV)
Intramuscular
Oral

Global Cancer Immunotherapy Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals & Clinics
Cancer Research Centers
Others

Global Cancer Immunotherapy Market Size & CAGR (2026-2033)

North America (Type, Application, Route of Administration, End User)
- US
- Canada
Europe (Type, Application, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Application, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Application, Route of Administration, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Application, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exelixis, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alnylam Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BeiGene, Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zai Lab Limited (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fate Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kura Oncology, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments